Skip to main content

Processa Pharmaceuticals, Inc.

PCSA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001533743

In the last 90 days, Processa Pharmaceuticals, Inc. insiders filed 5 open-market purchases and 0 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $498.3K in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Processa Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
5 filings
5 insiders, $25.9K in total
Open-market sells
0 filings
Insiders trading
5
Net value
+$25.9K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Processa Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Processa Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Ng George KChief Executive Officer17,092Aug 11, 202610
Gujrathi SheilaDirector–Jul 30, 20261
Yorke Justin WDirector353Jul 28, 20263
Skibsted RussellChief Financial Officer16,689Jul 28, 20269
Pannu GeraldineDirector2,391Jul 28, 20264
Neal James RDirector1,021Jul 28, 20264
Lin PatrickChief Business - Strategy Off13,113Jul 28, 202610
Guy WendyChief Administrative Officer14,394Jul 28, 202610
Baluch KhosoDirector2,528Jul 28, 20264
Young DavidPres. Research & Development21,729Jul 1, 20269
Bigora SianChief Development Officer7,481May 19, 20265
Stanker James HChief Financial Officer6,482Aug 2, 20240
Thompson VirgilDirector123,849IndirectJul 24, 20230
Floyd Robert MichaelChief Operating Officer82,267Feb 10, 20230
Islam KhalidDirector72,486Apr 19, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 16, 2026 (view filing)Jun 151 dayYoung DavidPres. Research & DevelopmentPPurchase+2.07K$2.22+$4.59K+12.1%19.2K after
Jul 1, 2026 (view filing)4:16 PM ETJun 301 dayYoung DavidPres. Research & DevelopmentPPurchase+2.53K$1.93+$4.88K+13.2%21.7K after
Jul 1, 2026 (view filing)4:17 PM ETJun 301 daySkibsted RussellChief Financial OfficerPPurchase+3.28K$1.93+$6.32K+24.4%16.7K after
Jul 1, 2026 (view filing)4:19 PM ETJul 1Same dayNg George KChief Executive OfficerPPurchase+3.06K$1.93+$5.90K+24.6%15.5K after
Jul 1, 2026 (view filing)4:19 PM ETJun 301 dayLin PatrickChief Business - Strategy OffPPurchase+2.11K$1.93+$4.06K+19.1%13.1K after
Jul 1, 2026 (view filing)4:20 PM ETJun 301 dayGuy WendyChief Administrative OfficerPPurchase+2.44K$1.93+$4.70K+20.4%14.4K after